ClinicalTrials.gg
RecruitingNCT07437547BPC-HAMSTRUpdated Feb 27, 2026

BPC 157 for Acute Hamstring Muscle Strain Repair

A Phase 2 interventional study of Pentadecapeptide BPC 157 and Placebo in Hamstring Muscle Strain and Skeletal Muscle Injury, sponsored by Hudson Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Hudson Biotech · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Read the detailed description

Acute hamstring strains are common in running- and field-based sports and often lead to prolonged time away from sport and a risk of recurrence. Preclinical research suggests that BPC 157 may influence pathways involved in tissue protection, angiogenesis, and repair. Human clinical evidence remains limited, so a controlled trial is needed to evaluate potential benefits and characterize safety in a musculoskeletal injury population. After screening and baseline assessments (including MRI confirmation of an acute grade II hamstring strain), eligible participants will be randomized 1:1 to receive subcutaneous BPC 157 or matching placebo once daily for 14 days. All participants will follow the same evidence-based rehabilitation protocol supervised by study physiotherapists. Clinical assessments will occur at Days 3, 7, 14, 28, and 56, with additional follow-up at 3 months after return-to-play for recurrence monitoring. Safety will be assessed through adverse event monitoring, vital signs, and standard laboratory tests. An independent Data and Safety Monitoring Committee will review unblinded safety data at predefined intervals.

02

Conditions studied

  • Hamstring Muscle Strain
  • Skeletal Muscle Injury

Browse trials for

Keywords

  • BPC 157
  • BPC-157
  • pentadecapeptide
  • muscle strain
  • hamstring injury
  • sports medicine
  • MRI
  • return to play
  • muscle repair
  • rehabilitation
03

In context

Sprains and Strains

246 studies on the registry are indexed under Sprains and Strains; 49 are open to participants now.

This study's planned enrollment of 120 is above the median of 60 across 162 interventional studies indexed under Sprains and Strains.

Browse Sprains and Strains studies →

Lead sponsor

Hudson Biotech is the lead sponsor of 8 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 45 years.
  • Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.
  • MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with .
  • Pre-injury physical activity >= 3 sessions/week or participation in organized recreational sport.
  • Willingness to follow the standardized rehabilitation protocol and attend all study visits.
  • For participants of : negative pregnancy test at baseline and agreement to use effective during dosing and for 30 days after last dose.

Exclusion criteria

Exclusion Criteria:

  • Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.
  • Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.
  • Prior hamstring strain on the index limb within the past 6 months.
  • Use of systemic , anabolic agents, -rich plasma, stem-cell products, or peptides/growth factors within 30 days prior to screening.
  • Known bleeding disorder or current therapeutic anticoagulation.
  • Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.
  • Known allergy or to components of the investigational product or placebo.
  • Pregnant or breastfeeding.
  • Current participation in another interventional clinical study or participation within 30 days prior to screening.
  • Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Arm 1: Experimental - BPC 157

    Participants receive investigational pentadecapeptide BPC 157 plus standardized rehabilitation.

    Drug: Pentadecapeptide BPC 157 · Drug: Placebo

  • Experimental
    Arm 2: Placebo Comparator - Placebo

    Participants receive matching placebo plus standardized rehabilitation.

    Drug: Pentadecapeptide BPC 157 · Drug: Placebo

Interventions

  • DrugPentadecapeptide BPC 157

    subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

  • DrugPlacebo

    subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

06

What researchers measure

Primary outcomes

  1. Time to return to unrestricted sport participation (days)

    defined as clearance by a blinded sports medicine clinician and completion of a standardized functional performance battery without pain-limited stopping.

    Time frame: 8 Weeks

  2. Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), measured by blinded central radiology review.

    Time frame: 14 Days

Secondary outcomes

  1. Change in pain during activity on a 0-10 Numeric Rating Scale (NRS; 0 = no pain, 10 = worst pain).

    Time frame: 56 Days

  2. Hamstring strength limb symmetry index (LSI) by isokinetic dynamometry

    Time frame: 56 Days

  3. Change in Lower Extremity Functional Scale (LEFS; 0-80, higher scores indicate better function)

    Time frame: 56 Days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Feb 27, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Feb 14, 2027
CompletionEst.
Feb 17, 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07437547
Lead sponsor
Hudson Biotech
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Feb 2, 2026
Primary completion
Feb 14, 2027 (estimated)
Completion
Feb 17, 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Seni S Lu, Phd
Contact
Seni-Lu@beijing-biotech.com
+86 13076790030

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion